TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript May 2, 2024 TG Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the TG Therapeutics Conference Call and Webcast. At this time all participants are […]
The company raised guidance for sales of its drug for relapsing multiple sclerosis.
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?